Advertisement

Archives of Gynecology and Obstetrics

, Volume 277, Issue 1, pp 47–53 | Cite as

The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns

  • N. Cenk SayınEmail author
  • M. Tunç Canda
  • Nefize Ahmet
  • Sezer Arda
  • Necdet Süt
  • Füsun G. Varol
Original Article

Abstract

Objective

This study was designed to investigate the relationship between the second trimester maternal serum markers and adverse pregnancy outcomes in healthy newborns.

Materials and methods

A total of 749 women who delivered in our institution with complete follow up and second-trimester triple marker test data available were included in the study. Women with multiple pregnancies, chronic diseases, diabetes mellitus, obesity, smokers and infants with chromosomal and congenital abnormalities were excluded. Maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) and unconjugated estriol (uE3) values were investigated in our cohort who developed preeclampsia (n = 28), gestational diabetes (GM) (n = 69), preterm labor-birth (n = 100), oligohydramnios (n = 37) and macrosomia (n = 59) by using receiver operating characteristic (ROC) curve analysis, with chi-square and Pearson’s correlation tests.

Results

Women with uE3 ≤ 1.26 MoM (P = 0.001, AUC = 0.666), HCG > 1.04 MoM (P = 0.032, AUC = 0.599) or AFP ≤ 0.69 MoM (P = 0.049, AUC = 0.600) values significantly developed oligohydramnios. Also, macrosomic infants were observed in women who had HCG values > 0.86 MoM (P = 0.047, AUC = 0.578). Patients with HCG > 1.04 MoM (P = 0.04, AUC = 0.565) and uE3 ≤0.88 MoM (P = 0.049, AUC = 0.571) developed GDM. HCG levels ≥2.5 or ≥3 MoM were significantly associated with the development of oligohydramnios [P = 0.005; OR = 4 (95% CI: 1.7–9.7)], [P = 0.008; OR = 4.9 (95% CI: 1.7–13.7)], respectively. When women with adverse (n = 237) and normal (n = 512) outcomes were compared there were significant differences in maternal serum AFP (1.40 ± 0.84 vs. 1.23 ± 0.75 MoM, P = 0.006) and uE3 values (1.38 ± 1.42 vs. 1.45 ± 0.98 MoM, P = 0.001).

Conclusions

Serum estriol, AFP or HCG values in triple test results may be associated with development of oligohydramnios, gestational diabetes and macrosomia in women with healthy and normal appearing fetuses.

Keywords

Turkish population Triple test Perinatal outcome 

Notes

Acknowledgment

Conflict of interest: The authors have no connection to any of the companies or products mentioned in this article. We (the authors) state that we had full control of all primary data and we agree to allow the Journal to review our data if requested.

References

  1. 1.
    Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD (2005) Williams obstetrics. 22nd edn. McGraw-Hill, New York pp 313–340Google Scholar
  2. 2.
    Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP et al (1999) Second-trimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181:968–974PubMedCrossRefGoogle Scholar
  3. 3.
    Onderoglu LS, Kabukçu A (1997) Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynecol Obstet 56:245–249CrossRefGoogle Scholar
  4. 4.
    Walter DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB (1996) The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816–822CrossRefGoogle Scholar
  5. 5.
    Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA (2000) Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 182:589–594PubMedCrossRefGoogle Scholar
  6. 6.
    Walton DL, Norem CT, Schoen EJ, Ray T, Colby CJ (1999) Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. N Engl J Med 341:2033–2036PubMedCrossRefGoogle Scholar
  7. 7.
    Spencer K (2000) Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse pregnancy outcome. Prenat Diagn 20:652–656PubMedCrossRefGoogle Scholar
  8. 8.
    American Diabetes Association (2003) Position statement: gestational diabetes mellitus. Diabetes Care 26(Suppl. 1):S103–S105Google Scholar
  9. 9.
    Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577PubMedGoogle Scholar
  10. 10.
    Wenstrom KD, Owen J, Boots LR, Dubard MB (1994) Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 171:1038–1041PubMedGoogle Scholar
  11. 11.
    Bernstein IM, Bart RA, Miller R, Capeless EL (1992) Elevated maternal serum alpha-fetoprotein: association with placental sonolucencies, fetomaternal hemorrhage, vaginal bleeding and pregnancy outcome in the absence of fetal anomalies. Obstet Gynecol 79:71–74PubMedGoogle Scholar
  12. 12.
    Huerta-Enochian G, Katz W, Erfurth S (2001) The association of abnormal α-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 184:1549–1553PubMedCrossRefGoogle Scholar
  13. 13.
    Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E (2003) Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 110:12–15PubMedCrossRefGoogle Scholar
  14. 14.
    Boyd PA (1992) Why might maternal serum AFP be high in pregnancies in which the fetus is normally formed? Br J Obstet Gynaecol 99:93–95PubMedGoogle Scholar
  15. 15.
    Kıran TSU, Bethel J, Bhal PS (2005) Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25:253–256PubMedCrossRefGoogle Scholar
  16. 16.
    Berkeley AS, Killackey MA, Cederqvist LL (1983) Elevated maternal serum α-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 146:859–861PubMedGoogle Scholar
  17. 17.
    Boyd PA, Keeling JW (1986) Raised maternal serum α-fetoprotein in the absence of fetal abnormality-placental founding: a quantitative morphometric study. Prenat Diagn 6:369–373PubMedCrossRefGoogle Scholar
  18. 18.
    Luckas MJM, Sandland R, Hawe J, Neilson JP, McFadyen IR, Meekins JW (1998) Fetal growth retardation and second trimester maternal serum human chorionic gonadotropin levels. Placenta 19:143–147PubMedCrossRefGoogle Scholar
  19. 19.
    Lepage N, Chitayat D, Kingdom J, Huang T (2003) Association between second-trimester isolated high maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 188:1354–1359PubMedCrossRefGoogle Scholar
  20. 20.
    Ashour AM, Lieberman ES, Wilkins Haug LE, Repke JT (1997) The value of elevated second-trimester β-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol 176:438–442PubMedCrossRefGoogle Scholar
  21. 21.
    Summers A, Huang T, Meier C, Wyatt PR (2003) The implications of a false positive second-trimester serum screen for Down syndrome. Obstet Gynecol 101:1301–1306PubMedCrossRefGoogle Scholar
  22. 22.
    Towner D, Gandhi S, El Kady D (2006) Obstetrics outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 194:1676–1682PubMedCrossRefGoogle Scholar
  23. 23.
    Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M (1992) The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 80:83–86PubMedGoogle Scholar
  24. 24.
    Liu DF, Dickerman LH, Redline RW (1999) Pathological findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. Am J Clin Pathol 111:209–215PubMedGoogle Scholar
  25. 25.
    Sayin NC, Varol FG, Duran R, Acunas B, Kurt I (2007) Perinatal outcome in women screened for gestational diabetes mellitus with normal or with one elevated glucose tolerance test value. J Turkish German Gynecol Assoc 8:38–43Google Scholar
  26. 26.
    Kowalczyk TD, Cabaniss ML, Cusmano L (1998) Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 91:396–400PubMedCrossRefGoogle Scholar
  27. 27.
    Kim SY, Kim SK, Lee JS, Kim IK, Lee K (2000) The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down’s syndrome. Yonsei Med J 41:226–229PubMedGoogle Scholar
  28. 28.
    Isouard G (1979) Measurement of serum levels of oestriol and human placental lactogen in the management of preeclamptic pregnancies. Med J Aust 2:401–404PubMedGoogle Scholar
  29. 29.
    Goodwin TM (1999) A role for estriol in human labor, term and preterm. Am J Obstet Gynecol 180:208–213CrossRefGoogle Scholar
  30. 30.
    Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA et al, for the FASTER Trial Research Consortium (2005) Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260–267PubMedGoogle Scholar
  31. 31.
    Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ (1995) Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers. Obstet Gynecol 86:255–258PubMedCrossRefGoogle Scholar
  32. 32.
    Salafia CM, Silberman C, Herrerra NE, Mahoney MJ (1988) Placental pathology at term associated with elevated midtrimester maternal serum AFP concentration. Am J Obstet Gynecol 158:1064–1066PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • N. Cenk Sayın
    • 1
    • 4
    Email author
  • M. Tunç Canda
    • 2
  • Nefize Ahmet
    • 1
  • Sezer Arda
    • 1
  • Necdet Süt
    • 3
  • Füsun G. Varol
    • 1
  1. 1.Department of Obstetrics and GynecologyTrakya UniversityEdirneTurkey
  2. 2.Kent HospitalIzmirTurkey
  3. 3.Department of BiostatisticsTrakya UniversityEdirneTurkey
  4. 4.Trakya Üniversitesi, Tıp FakültesiEdirneTurkey

Personalised recommendations